BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
McKinsey
Accenture
Daiichi Sankyo
Harvard Business School
Fuji
AstraZeneca
Dow
Colorcon
UBS

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,271,975

« Back to Dashboard

Which drugs does patent 9,271,975 protect, and when does it expire?

Patent 9,271,975 protects AKYNZEO and is included in one NDA.

This patent has fifty-four patent family members in thirty-seven countries.
Summary for Patent: 9,271,975
Title:Compositions and methods for treating centrally mediated nausea and vomiting
Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
Inventor(s): Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT)
Assignee: HELSINN HEALTHCARE SA (Lugano/Pazzallo, CH)
Application Number:14/069,970
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,271,975

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,271,975

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,623,826 Compositions and methods for treating centrally mediated nausea and vomiting ➤ Subscribe
8,951,969 Compositions and methods for treating centrally mediated nausea and vomiting ➤ Subscribe
9,186,357 Compositions and methods for treating centrally mediated nausea and vomiting ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,271,975

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
San Marino T201400112 ➤ Subscribe
Slovenia 2722045 ➤ Subscribe
Slovenia 2361090 ➤ Subscribe
Serbia 55206 ➤ Subscribe
Serbia 53491 ➤ Subscribe
Portugal 2722045 ➤ Subscribe
Portugal 2361090 ➤ Subscribe
Poland 2722045 ➤ Subscribe
Poland 2722044 ➤ Subscribe
Peru 14832012 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Healthtrust
Medtronic
Merck
Harvard Business School
QuintilesIMS
Baxter
Citi
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot